Wikisage, the free encyclopedia of the second generation, is digital heritage
Bezafibrate: Difference between revisions
Jump to navigation
Jump to search
(→ATC) |
m (→ATC) |
||
| Line 12: | Line 12: | ||
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure). | ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure). | ||
==ATC== | ==ATC== | ||
Lipid modyfying agents | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
|colspan=2| <center> | |colspan=2| <center> | ||
| Line 19: | Line 19: | ||
|} | |} | ||
<references/> | <references/> | ||
[[Category:Hepatic toxic]] | |||
Revision as of 01:01, 5 November 2015
Bezafibrate was originally developed as a drug for treatment of hyperlipidemia and used for the prevention of cardiovascular diseases This fibrate reduce triglyceride and riseHDL-cholesterol[1][2]
ursodeoxycholic acid and bezafibrate are under study in the treatment of biliar cyrrhosis (See Figure).
ATC
Lipid modyfying agents
- ↑ How Does Bezafibrate Affect the Plasma HDL Cholesterol Levels?
- ↑ Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
- ↑ Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
- ↑ Optimal drug regimens for primary biliary cirrhosis: a systematic review and network meta-analysis
- ↑ http://www.whocc.no/atc_ddd_index/?code=C10AB02